Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
2(17%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
8
67%
Ph phase_2
3
25%
Ph phase_3
1
8%

Phase Distribution

8

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
8(66.7%)
Phase 2Efficacy & side effects
3(25.0%)
Phase 3Large-scale testing
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(7)
Terminated(1)
Other(2)

Detailed Status

Completed7
Recruiting2
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (66.7%)
Phase 23 (25.0%)
Phase 31 (8.3%)

Trials by Status

terminated18%
completed758%
recruiting217%
unknown217%

Recent Activity

Clinical Trials (12)

Drug Details

Intervention Type
DRUG
Total Trials
12